SSA
CUE icon

Schonfeld Strategic Advisors’s Cue Biopharma CUE Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-800
Closed -$29.8K – 2105
2024
Q2 		$29.8K Buy
+800
New +$39.6K ﹤0.01% 1981
2022
Q4 		– Sell
-503
Closed -$34K – 2662
2022
Q3 		$34K Sell
503
-1,486
-75% -$128K ﹤0.01% 2681
2022
Q2 		$149K Buy
1,989
+706
+55% +$82.6K ﹤0.01% 2016
2022
Q1 		$188K Sell
1,283
-307
-19% -$65.1K ﹤0.01% 2003
2021
Q4 		$540K Buy
+1,590
New +$615K ﹤0.01% 1221

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Schonfeld Strategic Advisors's CUE Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 800 shares — an estimated $29.8K sold.

Schonfeld Strategic Advisors first reported a position in CUE in Q4 2021 and held it in 5 quarters. The position peaked at $540K in Q4 2021. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 800 Cue Biopharma shares in Q3 2024, an estimated $29.8K.
  • Schonfeld Strategic Advisors first reported a position in Cue Biopharma in Q4 2021 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Cue Biopharma position peaked at $540K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.